AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24283280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice quantity (0.5 g vs 1.5 g)
Number of subjects: 42
Study 21954166 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale Physical Activity Survey (YPAS)
Number of subjects: 310
Study 19523207 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat robotic gait orthosis
Number of subjects: 16
Study 19523207 — intervention group
Group type: COMPARATOR
Intervention: Manual-assisted body-weight supported treadmill training (BWSTT)
Number of subjects: 16
Study 17143175 — intervention group
Group type: EXPERIMENTAL
Intervention: AngQb (400 microg)
Number of subjects: 12
Study 17143175 — intervention group
Group type: EXPERIMENTAL
Intervention: AngQb (100 microg)
Number of subjects: 12
Study 17143175 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (1 mg/kg per day)
Number of subjects: 12
Study 17143175 — intervention group
Group type: COMPARATOR
Intervention: VLP alone
Number of subjects: 12
Study 15108979 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 4 kJ x kg(‐1) x h(‐1) for 2.5 h combined with skin‐surface warming
Number of subjects: 9
Study 15108979 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion combined with cutaneous cooling
Number of subjects: 9
Study 15108979 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion combined with skin‐surface warming
Number of subjects: 9
Study 15108979 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion combined with cutaneous cooling
Number of subjects: 9
Study 11451721 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (increased fruit, vegetables, and low-fat dairy; reduced saturated fat, total fat, and cholesterol)
Number of subjects: 436
Study 11451721 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 436
Study 11451721 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 436
Study 11451721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet
Number of subjects: 436
Study 9738579 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 356
Study 9738579 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 356
Study 8031555 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg, 20 mg)
Number of subjects: 20
Study 8031555 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (4 mg, 8 mg)
Number of subjects: 20
Study 2029111 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5 mg weekly, increased to 15 mg after 8 weeks if clinically effective)
Number of subjects: 64
Study 2029111 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (100 mg daily, increased to 150 mg after 8 weeks if clinically effective)
Number of subjects: 64
Study 2029111 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 64
Study 2029111 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 64
Study 318908 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 mg
Number of subjects: 125
Study 318908 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.5 mg
Number of subjects: 125
Study 318908 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1.0 mg
Number of subjects: 125
Study 318908 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 20 mg
Number of subjects: 125
Study 318908 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 40 mg
Number of subjects: 125
Study 318908 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.5 mg and 1.0 mg
Number of subjects: 125
Study 318908 — intervention group
Group type: COMPARATOR
Intervention: Meperidine group
Number of subjects: 125
Study 31094614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60
Study 31094614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60
Study 31094614 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin placebo
Number of subjects: 60
Study 28553076 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 μg/kg palonosetron
Number of subjects: 129
Study 28553076 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg/kg palonosetron
Number of subjects: 129
Study 28553076 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 μg/kg palonosetron and 15 μg/kg droperidol
Number of subjects: 129
Study 28553076 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 129
Study 25651245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate (TDF)
Number of subjects: 5029
Study 25651245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir-emtricitabine (TDF-FTC)
Number of subjects: 5029
Study 25651245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tenofovir (TFV) vaginal gel
Number of subjects: 5029
Study 25651245 — intervention group
Group type: COMPARATOR
Intervention: Oral TDF-FTC
Number of subjects: 5029
Study 23905525 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 4619
Study 23905525 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 4619
Study 23905525 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for BMI
Number of subjects: 4619
Study 23905525 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for metabolic syndrome
Number of subjects: 4619
Study 23905525 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise model
Number of subjects: 4619
Study 16466655 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 62
Study 16466655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12719051 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative active warming
Number of subjects: 30
Study 12719051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative warming only
Number of subjects: 30
Study 12719051 — intervention group
Group type: COMPARATOR
Intervention: No special precautions (control group)
Number of subjects: 30
Study 10028980 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mass antibiotic treatment (azithromycin, ciprofloxacin, metronidazole)
Number of subjects: 12726
Study 10028980 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamins/anthelmintic drug)
Number of subjects: 12726
Study 8897864 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine (800 mumol.kg-1.h-1)
Number of subjects: 7
Study 8897864 — intervention group
Group type: COMPARATOR
Intervention: Glycine (isonitrogenous infusion)
Number of subjects: 7
Study 1324895 — intervention group
Group type: COMPARATOR
Intervention: RT (45 Gy/15 fractions/3 weeks)
Number of subjects: 173
Study 1324895 — intervention group
Group type: EXPERIMENTAL
Intervention: RT and daily low dose of cDDP (6 mg/m2)
Number of subjects: 173
Study 6828981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin gluceptate
Number of subjects: 123
Study 6828981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole with tobramycin
Number of subjects: 123
Study 28799984 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (60 mg, Xylocaine 10% pump spray)
Number of subjects: 17
Study 28799984 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray (chlorhexidine gluconate 0.5% in 70% alcohol base)
Number of subjects: 17
Study 27609658 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 37
Study 27609658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 25882396 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil plus ofatumumab
Number of subjects: 447
Study 25882396 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil alone
Number of subjects: 447
Study 23078405 — intervention group
Group type: EXPERIMENTAL
Intervention: Play activities
Number of subjects: 53
Study 23078405 — intervention group
Group type: COMPARATOR
Intervention: No play activities (Control)
Number of subjects: 53
Study 21699717 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention delivered by practice nurses and healthcare assistants, consisting of behaviour change techniques designed to increase walking self-efficacy and help translate intentions into behaviour change.
Number of subjects: 400
Study 21699717 — intervention group
Group type: COMPARATOR
Intervention: Information provision control intervention, consisting of written materials promoting walking and a short unstructured discussion about increasing walking.
Number of subjects: 400
Study 21699717 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 400
Study 18706705 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin loading before PCI
Number of subjects: 445
Study 18706705 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment before PCI (Control group)
Number of subjects: 445
Study 16564621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 ml, 20mg/ml lidocaine and 12.5 microg/ml adrenaline)
Number of subjects: 35
Study 16564621 — intervention group
Group type: COMPARATOR
Intervention: Saline (1.5 ml, 9 mg/ml NaCl solution) (placebo)
Number of subjects: 35
Study 12971708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group exercise programme under the supervision of a physiotherapist for six weeks
Number of subjects: 51
Study 12971708 — intervention group
Group type: COMPARATOR
Intervention: Home physiotherapy programme (control group)
Number of subjects: 51
Study 11117586 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 0
Study 11117586 — intervention group
Group type: COMPARATOR
Intervention: Control (solid meal ingestion)
Number of subjects: 0
Study 9206239 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenxin decoction
Number of subjects: 122
Study 9206239 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 122
Study 1419014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine followed by IV lidocaine
Number of subjects: 40
Study 1419014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized placebo followed by IV lidocaine
Number of subjects: 40
Study 1419014 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized lidocaine followed by IV placebo
Number of subjects: 40
Study 1419014 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized placebo followed by IV placebo
Number of subjects: 40
Study 6537916 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric antibiotic treatment for fever
Number of subjects: 55
Study 30802277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced HIV prevention counseling (ERHTEC) every 3 months throughout follow‐up.
Number of subjects: 820
Study 30802277 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling at the time of HIV retesting.
Number of subjects: 820
Study 30105362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.1 to 0.4 mg per day)
Number of subjects: 36
Study 30105362 — intervention group
Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 36
Study 30105362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 36
Study 27438627 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS solution 2 hours before surgery
Number of subjects: 24
Study 27438627 — intervention group
Group type: COMPARATOR
Intervention: Control group (fasting)
Number of subjects: 24
Study 25440377 — intervention group
Group type: EXPERIMENTAL
Intervention: 15g/day of E. angustifolia L. medulla for 8 weeks
Number of subjects: 90
Study 25440377 — intervention group
Group type: EXPERIMENTAL
Intervention: 15g/day of E. angustifolia L. whole fruit for 8 weeks
Number of subjects: 90
Study 25440377 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 90
Study 23128099 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 14
Study 23128099 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie yoghurt (control)
Number of subjects: 14
Study 23128099 — intervention group
Group type: EXPERIMENTAL
Intervention: Other test meals (rolled oats, sugar, cornflakes, walnuts)
Number of subjects: 14
Study 23128099 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals (including protein, rolled oats, sugar, cornflakes, walnuts)
Number of subjects: 14
Study 20946926 — intervention group
Group type: EXPERIMENTAL
Intervention: High caloric food pictures
Number of subjects: 0
Study 20946926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low caloric food pictures
Number of subjects: 0
Study 20946926 — intervention group
Group type: COMPARATOR
Intervention: Peripheral measures
Number of subjects: 0
Study 18056193 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 i.v. infusion over 1 hour)
Number of subjects: 101
Study 18056193 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) in CAR, HNF4alpha, and PXR
Number of subjects: 101
Study 15957134 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-Treatment Group (ITG)
Number of subjects: 56
Study 15957134 — intervention group
Group type: COMPARATOR
Intervention: Deferred-Treatment Group (DTG)
Number of subjects: 56
Study 12107244 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp (glucose lowered to 2.5 mmol/liter)
Number of subjects: 16
Study 12107244 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (glucose maintained at 5 mmol/liter)
Number of subjects: 16
Study 12107244 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (80 mU/m(2).min) during euglycemic clamp
Number of subjects: 16
Study 12107244 — intervention group
Group type: COMPARATOR
Intervention: Matched saline infusion (control group)
Number of subjects: 16
Study 10221380 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of abdominal aortic aneurysm (AAA) and elongation of the internal carotid artery (e‐ICA) in 25 patients (58.1%)
Number of subjects: 43
Study 10221380 — intervention group
Group type: COMPARATOR
Intervention: Control group of 141 e‐ICA subjects with no AAA
Number of subjects: 43
Study 7554700 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loratadine every morning plus 500 mg erythromycin stearate every 8 hours
Number of subjects: 24
Study 7554700 — intervention group
Group type: COMPARATOR
Intervention: 10 mg loratadine every morning plus placebo every 8 hours
Number of subjects: 24
Study 7554700 — intervention group
Group type: COMPARATOR
Intervention: placebo every morning plus 500 mg erythromycin stearate
Number of subjects: 24
Study 1980981 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate (CP)
Number of subjects: 0
Study 1980981 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude coal tar (CT)
Number of subjects: 0
Study 1980981 — intervention group
Group type: COMPARATOR
Intervention: Dithranol (10% for 2 hours)
Number of subjects: 0
Study 6243916 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ampicillin sodium
Number of subjects: 398
Study 6243916 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid sutures
Number of subjects: 398
Study 6243916 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk sutures
Number of subjects: 398
Study 6243916 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative seromas or hematomas
Number of subjects: 398
Study 6243916 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomies
Number of subjects: 398
Study 6243916 — intervention group
Group type: COMPARATOR
Intervention: Hernia repairs
Number of subjects: 398
Study 30566417 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 84
Study 30566417 — intervention group
Group type: COMPARATOR
Intervention: Second-generation oral antipsychotics
Number of subjects: 84
Study 28363637 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg DSM265 1 day before CHMI
Number of subjects: 22
Study 28363637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (250-100 mg) 1 day before CHMI
Number of subjects: 22
Study 28363637 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg DSM265 7 days before CHMI
Number of subjects: 22
Study 28363637 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 day before CHMI
Number of subjects: 22
Study 28363637 — intervention group
Group type: COMPARATOR
Intervention: Placebo 7 days before CHMI
Number of subjects: 22
Study 25826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic diclofenac
Number of subjects: 10
Study 25826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic ketorolac
Number of subjects: 10
Study 25826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand bromfenac
Number of subjects: 10
Study 25826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand nepafenac
Number of subjects: 10
Study 23873711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-affective symptoms of depression in patients younger than 70 years
Number of subjects: 1823
Study 23873711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopelessness in patients younger than 70 years
Number of subjects: 1823
Study 23873711 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic symptoms in patients younger than 70 years
Number of subjects: 1823
Study 23873711 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, disease severity, and comorbidities in patients 70 years or older
Number of subjects: 1823
Study 23873711 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcome for patients (both age groups)
Number of subjects: 1823
Study 21378389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target glucose 80‐120 mg/dl)
Number of subjects: 115
Study 21378389 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control (target glucose 180 mg/dl or less)
Number of subjects: 115
Study 21378389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 115
Study 19286590 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of a Phase IIb trial of recombinant activated Factor VII
Number of subjects: 90
Study 17166646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 93
Study 15518835 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK fusion (Group A)
Number of subjects: 180
Study 15518835 — intervention group
Group type: EXPERIMENTAL
Intervention: AICG fusion and plate fixation (Group B)
Number of subjects: 180
Study 15518835 — intervention group
Group type: COMPARATOR
Intervention: AICG only (Group C)
Number of subjects: 180
Study 11449027 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS of left PFC
Number of subjects: 0
Study 11449027 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS of right PFC
Number of subjects: 0
Study 11449027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood self-rating
Number of subjects: 0
Study 9116805 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation (NMS) of the finger and wrist flexors and extensors for 30 minutes
Number of subjects: 8
Study 9116805 — intervention group
Group type: COMPARATOR
Intervention: Limb elevation for 30 minutes
Number of subjects: 8
Study 8429639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance (BI)
Number of subjects: 10
Study 3315698 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, vincristine and prednisolone (EVP)
Number of subjects: 100
Study 3315698 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine and prednisolone (CVP)
Number of subjects: 100
Study 3315698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
Number of subjects: 100
Study 3315698 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP)
Number of subjects: 100
Study 3315698 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 100
Study 31810741 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 48
Study 31810741 — intervention group
Group type: COMPARATOR
Intervention: Control (no periodontal treatment)
Number of subjects: 48
Study 31810741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergroup comparison
Number of subjects: 48
Study 29549863 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite Awareness Treatment (AAT)
Number of subjects: 31
Study 29549863 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WAIT)
Number of subjects: 31
Study 26130657 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (n=14), 45 minutes per session, five days a week for four weeks
Number of subjects: 28
Study 26130657 — intervention group
Group type: COMPARATOR
Intervention: Land-based therapy (Control group, n=14), 45 minutes per session, five days a week for four weeks
Number of subjects: 28
Study 25577782 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol 100-200mg (C group)
Number of subjects: 102
Study 25577782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5-5mg (B group)
Number of subjects: 102
Study 23632946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 0
Study 23632946 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular interferon beta (IFNβ)‐1a
Number of subjects: 0
Study 19662337 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA antigen
Number of subjects: 100
Study 19662337 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF
Number of subjects: 100
Study 19662337 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP‐3
Number of subjects: 100
Study 19662337 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 100
Study 19662337 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP‐9
Number of subjects: 100
Study 18621519 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg twice daily for 5 days
Number of subjects: 22
Study 16085366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and contingency management (CM)
Number of subjects: 81
Study 16085366 — intervention group
Group type: COMPARATOR
Intervention: Control (neither CBT nor CM)
Number of subjects: 81
Study 12888042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/ml ICG
Number of subjects: 28
Study 12888042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml ICG
Number of subjects: 28